MEDTRONIC INC

Form 4

January 28, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

0.5

January 31, Expires: 2005

OMB APPROVAL

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or	Type	Responses)
-----------	------	------------

may continue.

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Powell Kendall J Issuer Symbol MEDTRONIC INC [MDT] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) X_ Director 10% Owner Other (specify Officer (give title GENERAL MILLS., ONE 01/26/2015 below) GENERAL MILLS BLVD (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting MINNEAPOLIS, MN 55426 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3.	4. Securities A compr Disposed of (Instr. 3, 4 and	cquire (D) 5)	-	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	01/26/2015		Code V	Amount 19,601.464	or (D)	Price	(Instr. 3 and 4) 0	D	
Common stock	01/26/2015		D	3,000	D	<u>(1)</u>	0	I	By Spouse Rev Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: MEDTRONIC INC - Form 4

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

8. I De Sec (In

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Transaction Derivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock option (right to buy)	\$ 51.61	01/26/2015		D	2,713	(2)	06/22/2017	Common stock	2,713	
Stock option (right to buy)	\$ 51.61	01/26/2015		D	264	(3)	06/22/2017	Common stock	264	
Stock option (right to buy)	\$ 52.84	01/26/2015		D	1,010	<u>(4)</u>	09/01/2017	Common stock	1,010	
Stock option (right to buy)	\$ 50.34	01/26/2015		D	1,590	<u>(5)</u>	04/28/2018	Common stock	1,590	
Stock option (right to buy)	\$ 29.96	01/26/2015		D	2,671	<u>(6)</u>	04/27/2019	Common stock	2,671	
Stock option (right to buy)	\$ 44.13	01/26/2015		D	1,813	<u>(7)</u>	05/03/2020	Common stock	1,813	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Powell Kendall J GENERAL MILLS,	X						

Reporting Owners 2

ONE GENERAL MILLS BLVD MINNEAPOLIS, MN 55426

Signatures

/s/ Rhonda L. Ingalsbe, Attorney-in-fact

01/28/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents shares of Medtronic, Inc. ("Medtronic"), including deferred units credited under a Medtronic, Inc. equity-based plan to be paid in Medtronic, Inc. common stock upon the director's resignation or retirement as well as a balance increase of 3,263.44 shares since the director's last Form 4 filing due to exempt transactions such as dividend reinvestment, disposed of pursuant to the merger (the "Merger) of a wholly-owned subsidiary of Medtronic plc ("New Medtronic") with and into Medtronic, with Medtronic surviving as a wholly-owned

- a wholly-owned subsidiary of Medtronic pic ("New Medtronic") with and into Medtronic, with Medtronic surviving as a wholly-owned subsidiary of New Medtronic, in exchange for ordinary shares of New Medtronic, which was consummated after and conditioned on New Medtronic's acquisition of Covidien plc, by means of a "scheme of arrangement", an Irish statutory procedure under the Companies Act of 1963. At the effective time of the Merger, each Medtronic common share (including each deferred unit) was cancelled and converted into the right to receive one New Medtronic ordinary share.
- This option, which was fully vested at the effective time of the Merger, was assumed by New Medtronic in the Merger and converted into (2) an option to purchase 2,713 ordinary shares of New Medtronic for \$51.61 per share with the same terms and conditions as the original Medtronic stock option.
- This option, which was fully vested at the effective time of the Merger, was assumed by New Medtronic in the Merger and converted into (3) an option to purchase 264 ordinary shares of New Medtronic for \$51.61 per share with the same terms and conditions as the original Medtronic stock option.
- This option, which was fully vested at the effective time of the Merger, was assumed by New Medtronic in the Merger and converted into (4) an option to purchase 1,010 ordinary shares of New Medtronic for \$52.84 per share with the same terms and conditions as the original Medtronic stock option.
- This option, which was fully vested at the effective time of the Merger, was assumed by New Medtronic in the Merger and converted into (5) an option to purchase 1,590 ordinary shares of New Medtronic for \$50.34 per share with the same terms and conditions as the original Medtronic stock option.
- This option, which was fully vested at the effective time of the Merger, was assumed by New Medtronic in the Merger and converted into (6) an option to purchase 2,671 ordinary shares of New Medtronic for \$29.96 per share with the same terms and conditions as the original Medtronic stock option.
- This option, which was fully vested at the effective time of the Merger, was assumed by New Medtronic in the Merger and converted into (7) an option to purchase 1,813 ordinary shares of New Medtronic for \$44.13 per share with the same terms and conditions as the original Medtronic stock option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3